SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-000444
Filing Date
2022-01-26
Accepted
2022-01-26 09:15:21
Documents
13
Period of Report
2022-01-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20220125x8k.htm   iXBRL 8-K 32640
2 EX-99.1 ibio-20220125xex99d1.htm EX-99.1 24764
  Complete submission text file 0001558370-22-000444.txt   179884

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20220125.xsd EX-101.SCH 2767
4 EX-101.LAB ibio-20220125_lab.xml EX-101.LAB 13524
5 EX-101.PRE ibio-20220125_pre.xml EX-101.PRE 10120
7 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20220125x8k_htm.xml XML 4651
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 22555965
SIC: 2834 Pharmaceutical Preparations